THE OLMESARTAN FOR THE TREATMENT OF ARTERIAL HYPERTENSION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper discusses how to choose rational pharmacotherapy for arterial hypertension. It considers the abilities of angiotensin II receptor blockers to reduce a cardiovascular risk and to protect organs. Publications on olmesartan that has clinically proven its efficacy and safety versus placebo and drugs from other classes are reviewed. The antihypertensive efficacy of olmesartan is combined with additional organ-protective properties, with nephroprotective ones in particular, which expands its clinical applications.

Full Text

Restricted Access

About the authors

T. Morozova

I.M. Sechenov First Moscow State Medical University

Email: temorozova@gmail.com
Professor of medicine

T. Andrushchishina

I.M. Sechenov First Moscow State Medical University

PhD

References

  1. Диагностика и лечение артериальной гипертонии. Рекомендации РМОАГ/ВНОК, 4-й пересмотр. - 2010.
  2. Ball K., Williams P., Stumpe K. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives // J. Hypertens. - 2001; 19 (1): 49-56.
  3. Brenner B., Cooper M., de Zeeuw D. et al. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) // N. Engl. J. Med. - 2001; 345: 861-69.
  4. Brunner H., Arakawa К. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals // Clin. Drug Invest. - 2006; 26 (4): 185-93.
  5. Chrysant S., Marbury T. The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-tomoderate hypertension // Am. J. Hypertens. - 2002; 15: A57 (аbstr.).
  6. Smith D., Dubiel R., Jones М. Use of 24-hour ambulatory plod pressure monitoring to assess antihypertensive efficacy. A comparison of olmesartan medoxomil, losartan potassium, valsartan and irbesartan // Am. J. Cardiovasc. Drugs. - 2005; 5 (1): 41-50.
  7. Granger C., McMurray J. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial // Lancet. - 2003; 362: 772-76.
  8. Haralambos P. Gavras, Salernob C. The angiotensin II Type 1 receptor blocker losartan in clinical practice: a review // Clin. Ther. 1996; 18 (6): 1058-67.
  9. Julius S., Kjeldsen S. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE // Lancet. - 2004; 363: 2022-31.
  10. Nakashima H., Kumagai K. Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model // Circ. J. - 2007; 71 (12): 1977-82.
  11. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers // Am. J. Hypertens. - 2000; 13 (1 Pt 2): 18-24.
  12. Pitt B. et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) //. Lancet. -1997; 349: 747-52.
  13. Puchler К., Laeis Р., Witte P. et al. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotesin II antagonist, in salt-restricted hypertensive patients // J.of Hypertension. - 1997; 15 (2): 1809-12.
  14. Ritz E., Viberti G., Ruilope L. et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study // Diabetologia. - 2010; 53 (1): 49-57; еpub 2009, оct. 30.
  15. Scholze J., Schaefer A., Kreutz R. Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients // Expert Opin Drug. Saf. - 2011.
  16. Van Mieghem W. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension (Abstract) // J. Hypertens. - 2001; 19 (1): 152.
  17. Von Bergmann K., Laeis P., Püchler K. et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil // J. Hypertens. - 2001; 19 (1): 33-40.
  18. Warner G., Jarvis B. Olmesartan medoxomil // Drugs. - 2002; 62 (9): 1345-53; discus. 1354-56.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies